Highlights

  • Q2 FY2026 revenue declined year-over-year, reflecting marketing shifts toward newly launched EXXUA therapy.
  • ADHD and pediatric portfolios recorded reduced revenue as promotional focus changed across segments.
  • EXXUA generated initial stocking revenue following mid-December 2025 commercial availability.

Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on therapies addressing central nervous system disorders, announced operational and financial results for the second quarter of fiscal 2026. The update included financial performance details alongside progress on the United States commercialization of EXXUA, an FDA-approved treatment for major depressive disorder (MDD) in adults.

Net revenue for the quarter totaled USD 15.2 million, compared with USD 16.2 million reported in the corresponding period of fiscal 2025. The company’s ADHD product portfolio generated USD 13.2 million in revenue, slightly lower than USD 13.8 million in the previous year’s quarter. The decline was primarily linked to reduced promotional emphasis and prescription volume adjustments as commercial resources were redirected toward EXXUA. Price adjustments and gross-to-net improvements partially offset these declines.

Revenue from the pediatric portfolio reached USD 1.7 million during the quarter, compared with USD 2.4 million in the prior-year period. The reduction reflected limited marketing activity for legacy pediatric products as the company adjusted its commercial priorities.

EXXUA, introduced commercially in mid-December 2025, contributed approximately USD 0.2 million in net revenue, largely associated with initial distributor stocking. Sales force training supporting the product rollout was completed in mid-January 2026. The therapy represents a selective serotonin 5HT1a receptor agonist approved for treating MDD, marking a new pharmacological classification within the treatment segment.

Gross profit during Q2 FY2026 was USD 9.6 million, representing 63% of net revenue, compared with USD 10.8 million, or 66% of revenue, in the prior-year quarter. The decline in gross margin percentage was influenced by lower overall revenue, marketing reprioritization, and transition-related costs associated with the Adzenys XR-ODT authorized generic expansion.

Operating expenses, excluding amortization and restructuring costs, increased to USD 11.1 million from USD 10.2 million year-over-year, reflecting spending associated with the EXXUA launch and commercialization infrastructure. The company reported a net loss of USD 10.6 million during the quarter, compared with net income of USD 0.8 million in the previous year. The change was largely influenced by an USD 8.2 million derivative warrant liability loss tied to stock price movements.

Adjusted EBITDA for the quarter was negative USD 0.8 million compared with positive USD 1.3 million in Q2 FY2025. Cash and cash equivalents totaled USD 30.0 million as of December 31, 2025, compared with USD 31.0 million at the start of the fiscal year.